CN101181385A - Medicament for dispelling scar and preparation method thereof - Google Patents
Medicament for dispelling scar and preparation method thereof Download PDFInfo
- Publication number
- CN101181385A CN101181385A CNA2007101930440A CN200710193044A CN101181385A CN 101181385 A CN101181385 A CN 101181385A CN A2007101930440 A CNA2007101930440 A CN A2007101930440A CN 200710193044 A CN200710193044 A CN 200710193044A CN 101181385 A CN101181385 A CN 101181385A
- Authority
- CN
- China
- Prior art keywords
- medicine
- proportions
- preparation
- cicatrix
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 231100000241 scar Toxicity 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 47
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 27
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 11
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 10
- 229940099259 vaseline Drugs 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 26
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 13
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 13
- 230000001804 emulsifying effect Effects 0.000 claims description 12
- 239000009969 fructus bruceae Substances 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 10
- 239000010238 camphora Substances 0.000 claims description 9
- 229940025250 camphora Drugs 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000013521 mastic Substances 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 239000005022 packaging material Substances 0.000 claims description 4
- 208000032544 Cicatrix Diseases 0.000 abstract description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract description 2
- 238000007493 shaping process Methods 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000723346 Cinnamomum camphora Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 240000005809 Prunus persica Species 0.000 abstract 1
- 244000097577 Rhus javanica Species 0.000 abstract 1
- 235000010889 Rhus javanica Nutrition 0.000 abstract 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- 229930008380 camphor Natural products 0.000 abstract 1
- 229960000846 camphor Drugs 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 230000037387 scars Effects 0.000 abstract 1
- 210000000589 cicatrix Anatomy 0.000 description 28
- 230000000694 effects Effects 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 17
- 208000003251 Pruritus Diseases 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 208000002260 Keloid Diseases 0.000 description 8
- 206010023330 Keloid scar Diseases 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 210000000835 hypertrophic cicatrix Anatomy 0.000 description 8
- 210000001117 keloid Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 229960001866 silicon dioxide Drugs 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229960001660 histamine phosphate Drugs 0.000 description 5
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 4
- 206010053615 Thermal burn Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000001139 anti-pruritic effect Effects 0.000 description 4
- 239000003908 antipruritic agent Substances 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 210000000264 venule Anatomy 0.000 description 4
- 239000003871 white petrolatum Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- CJDPJFRMHVXWPT-UHFFFAOYSA-N barium sulfide Chemical compound [S-2].[Ba+2] CJDPJFRMHVXWPT-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000006413 Prunus persica var. persica Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- -1 vaseline Chemical compound 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for removing scars caused by various reasons and a preparation method thereof. The invention is prepared by the raw materials by weight proportion: 100 to 500 proportions of Peach seed, 50 to 300 proportions of java brucea fruit, 5 to 50 proportions of borneol, 5 to 50 proportions of camphor, 30 to 300 proportions of crystal soda, 200 to 600 proportions of glycerin, 100 to 500 proportions of vaseline, 5 to 50 proportions of octodecyl alcohol and 5 to 50 proportions of glycerin monostearate. The invention has the advantages of easy use and being not limited by the scar shaping time and the shaping reason.
Description
Technical field
The present invention relates to a kind of medicine of dispeling the cicatrix that stays because of a variety of causes and preparation method thereof.
Background technology
People leave over various cicatrixes down because of reasons such as burn, scald, carbuncle sore, wound, operations on human body surface in daily life, work, even form hard, irregular swollen thing, the patient itches bitterly unbearable, and contracture deformity can take place, and produces the physiological function obstacle.These decrease the capacitive disease, and contemporary Chinese and western medicine does not all have fine very ideal Therapeutic Method.Domestic symptoms accompanied cicatrix patient is numerous now, and the whole world estimates at tens million of patients, causes serious mind ﹠ body misery, has a strong impact on work and life, causes no small loss for family and society.Though at present the various methods of treatment cicatrix have a lot, all there are weak curative effect, problem that side effect is big.According to theory of Chinese medical science as can be known, dispeling scar should be with promoting blood circulation and breaking stagnation, and the softening the hard mass removing food stagnancy is the rule of treatment, can soften scar tissue with this, improves keloid and contracture, eliminates pruritus, reaches the health-care recovery effect.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art and provide a kind of easy to use, safe and reliable, cost is low, nonirritant, effect obviously, determined curative effect and the medicine and preparation method thereof of the dispeling scar of treatment and rehabilitation effect is arranged, to alleviate cicatrix patient's misery, satisfy the needs of health care beauty treatment.
The object of the present invention is achieved like this:
Medicine of a kind of dispeling scar and preparation method thereof is prepared from by weight by following raw materials:
Semen Persicae 100-500 part Fructus Bruceae 50-300 part Borneolum Syntheticum 5-50 part
Camphora 5-50 part alkalium 30-300 part glycerol 200-600 part
Vaseline 100-500 part octadecanol 5-50 part glyceryl monostearate 5-50 part.
A kind of preparation method of medicine of above-mentioned dispeling scar is characterized in that its preparation method is as follows:
1, squeezing Semen Persicae and Fructus Bruceae are got oil, add Borneolum Syntheticum, Camphora grinding, get mixed liquor;
2, take by weighing vaseline, glyceryl monostearate, octadecanol, the mixed liquor that adds step 1 carries out heating and melting in pot;
3, take by weighing glycerol and alkalium mixing mixing batter;
4, with the gains of step 3 to the emulsifying pot, again with the gains of step 2 to the emulsifying pot, emulsifying;
5, cooling, check, canned.
In step 5, with the mastic embedding in sebific duct or other satisfactory packaging materials.
The present invention has following good effect:
One, clinical verification of the present invention is reported as follows:
(1), purpose:,, and conclude with its effect of definite understanding, safety and untoward reaction for the present invention is enlarged checking.
(2), case is selected:
1, indication: the cicatrix that reasons such as burn, scald, carbuncle sore, wound stay, hypertrophic cicatrix and keloid etc.
2, diagnostic criteria:
(1), have burn, scald, carbuncle sore, wound medical history person, and have cicatrix body constitution person;
(2), the skin horizontal direction or the vertical direction of wound surface convalescent period or the appearance of reparation back are soaked into the hard tuberosity or the speckle that exceed skin of propagation;
(3), skin lesion is with pruritus or pigmentation.
3, include standard in:
(1), all possess above-mentioned (1), (2) or three persons;
(2), the age was at 8 years old to 65 years old.
4, exclusion standard:
(1), cicatrix patient wound does not heal or the infected of festering is arranged;
(2), actute infection heat pyrexia patient is arranged;
(3), on inspection confirm to suffer from tumor, heavy and angiopathy, metabolic disease, hemorrhage, hepatopathy, nephropathy etc.;
(4), suffer from psychotic disorder and can not finish the observer;
(5), gestation or women breast-feeding their children are to this medicine allergy sufferers below 8 years old and the over-65s person age;
(6), all standards of including in that do not meet, not medication in accordance with regulations can't be judged that curative effect or data are not congruent to affect the treatment or safety judgement person.
(3), observation of curative effect:
1, safety is observed
(1) general health check-up project; (2) hematuria routine; (3) liver, kidney function test.
2, observation of curative effect
(1) speckle or scleroma size variation; (2) cicatrix firmness change; (3) the calm pigment alteration of cicatrix; (4) antipruritic; (5) recovery from dysfunction situation.
(4), methods of clinical observation:
1, fixed 3 experimental units of clinical trial, each unit example number is no less than 40 examples (30 examples are organized in treatment, matched group 10 examples).Experimenter's separating tests group and matched group.
2, administrated method: medicine of the present invention and control drug (blank) secondary every day, divide early, directly embrocate this cream on cicatrix evening, do not need the external application gauze, exposes treatment, continuous 30 days is a course of treatment, two courses of treatment of clinical observation are as efficacy determination.
3, points for attention: (1) wound not healing person is avoided usefulness; (2) avoid inlet, avoid and be strayed into eyes; (3) infant is avoided usefulness; (4) irritated as using this product to occur, pain takes place, itch, pimple, local edema etc. can reduce consumption or stop using; (5) deposit and to locate in the cool place.
(5), curative effect determinate standard:
1, produce effects: cicatrix attenuation, the obvious deliquescing of quality.
2, effective: cicatrix is attenuation slightly, but the gargalesthesia disappearance, pigment shoals.
3, invalid: treatment back symptom variation is little.
(6), result of the test:
Treat cicatrix patient 100 examples altogether, hypertrophic cicatrix 41 examples wherein, keloid 59 examples, cicatrix 162 places take place in 100 routine patients altogether, wherein facial 83 places, trunk 20 places, extremity 59 places.Age is at 8～56 years old, male's 44 examples.Women's 56 examples.Pathogenic factor is seen (78/100) with burn and other wound more.
Matched group 30 examples, male's 12 examples, women's 18 examples.Hypertrophic cicatrix 17 examples, keloid 13 examples.
Table 1 treatment group and matched group Comparison of therapeutic
| Produce effects (routine number) | Effectively (routine number) | Invalid (routine number) | Effectively total | ||
| The example number | Percentage rate | ||||
| Treatment group (n=100) | 37 | 44 | 19 | 81 | 81.00 |
| Matched group (n=30) | 3 | 5 | 22 | 30 | 26.67 |
Table 2 hypertrophic cicatrix and keloid Comparison of therapeutic
| Produce effects (routine number) | Effectively (routine number) | Invalid (routine number) | Effectively total | ||
| The example number | Percentage rate | ||||
| Hypertrophic cicatrix (n=41) | 20 | 14 | 7 | 34 | 82.95 |
| Keloid (n=59) | 17 | 30 | 12 | 47 | 79.66 |
(7), discuss
1, treats hypertrophic cicatrix and keloid at present ideal Therapeutic Method and medicine are seldom arranged.The clinical effective medicine (effective percentage 81.00%) that provides is provided in the present invention, obviously is better than the contrast treatment, for the clinical treatment cicatrix has increased a powerful measure.
2, hypertrophic cicatrix and keloid therapeutic outcome are approaching, the statistical procedures no significant difference.
3, external of the present invention is safe and effective, the non-stimulated and side effect of most patients, and only small number of patients can have temporary local pruritus.
Characteristics of the present invention: (1) is easy to use; (3) be not subjected to the restriction of cicatrization time; (4) formed the restriction of reason hardly.
Two, Pharmacodynamic test of active extract data of the present invention
(1) the present invention causes the influence of granulation hyperplasia model mice to medical silica-gel
Summary: cause local proliferation of fibrous tissue for the mouse subcutaneous injection medical silica-gel, simulate cicatrization from pathology, smeared the present invention on this basis continuous one month, granulation dissipates in the visible skin corium of microscopically, collagen fiber reduce, loose connective tissue and appendages of skin demutation point out this medicine that scar tissue is had the diffusing long-pending effect of certain softening the hard mass.
1, purpose: cicatrix mainly shows as fibroblast proliferation on pathology, forms a large amount of collagen fiber, and the appendages of skin reduce and lose normal organizational structure.Because of not seeing the bibliographical information that the cicatrix animal pattern is arranged, laboratory once all can not make the local cicatrix that forms of mice with several different methods such as scald, chemical burns, so the method that adopts medical silica-gel to be injected under the animal skins causes proliferation of fibrous tissue, the pathology of simulation cicatrix change, and smear on this basis to be subjected to reagent to observe this medicine to " cicatrix " histological influence.
2, medicine:
(1) the present invention and excipient (forming) by glycerol, white vaseline, octadecanol, glyceryl monostearate.
(2) chromatographic silica gel: white powder, be made into 20% aseptic suspension solution, use for subcutaneous injection.
3, animal: white mice, male, body weight 24-28g is provided by Experimental Animal Center.Conventional feed is fed, and drinking-water is not limit, 22-25 ℃ of experiment room temperature, relative humidity 50-60%.
4, grouping and method:
Grouping: 80 animals are divided into 2 groups at random, 40 every group.
(1) excipient matched group (model group): 0.1g/d * 30 local topicals.
(2) of the present invention group: 0.1g/d * 30 local topicals.
Method:
1) 20% silicone fluid in white mice back subcutaneous injection 0.5ml/ only.
2) get 5 animals every group of 2,4,6,8 weekends of injection behind the silica gel at every turn, draw neck to put to death, get the skin at injection silica gel position and do the pathology cut sections for microscopic examination, observe its histology and change, to determine whether to form " cicatrix " model.
3) formed model (, confirming 6-8 week can form model behind the injection silica gel) as confirming, then begun by the group medicine for external application continuous one month through giving test repeatedly.
4) animal cropping secondary weekly, and respectively at last every group of local skin of getting 5 animals around second week behind the coating, the at every turn to do the pathology cut sections for microscopic examination, to observe the effect of this medicine.
5, result or conclusion: give continuous month of model mice partial smearing the present invention, histopathologic examination, find that this medicine can promote that granulation dissipates in the skin corium, collagen fiber reduce, make loose connective tissue and appendages of skin demutation, point out this medicine that scar tissue is had certain softening the hard mass removing food stagnancy effect.
(2) antiinflammatory action test of the present invention---agar method
Summary: subcutaneous injection agar, cause the rat chronic nonspecific inflammation, be coated with outward with the present invention, the trend that alleviates agar granuloma weight is arranged in continuous 14 days.
1, purpose: give rat skin lower injection agar, can cause the local granuloma similar, observe behind coating the present invention influence to granuloma weight to clinical later stage pathological change.
2, medicine:
(1) the present invention and excipient (forming) by glycerol, white vaseline, octadecanol, glyceryl monostearate.
(3) agar: be made into 2% solution with NS during experiment, scalding is standby.
3, animal: male Wistar rat, body weight 170-200g is provided by Experimental Animal Center.22-25 ℃ of experiment room temperature, conventional feed, amount of drinking water is not limit.
4, grouping and method:
Grouping: 16 animals are divided into 2 groups at random, 8 every group.
(1) excipient matched group (model group): glycerol etc. are coated with for 0.2g/ time * 14 innings.
(2) of the present invention group: be coated with for 0.2g/ time * 14 innings.
Method: each Mus back cropping of experiment proxima luce (prox. luc), about 4 * the 5cm2 of area, next day is the sterile working under the shallow fiber crops of ether, in the agar solution 2ml of back center line subcutaneous injection 2%, and smears relative medicine by group, once a day, continuous 14 days, dissected animal, separate granuloma agar embryo in 15th, press the 100g body weight and calculate weight in wet base, learn by statistics and handle the difference that compares medication group and model control group.
5, result or conclusion: give the continuous application of rat 14 days with the present invention, can alleviate the granulomatous weight of agar, illustrate that this medicine has the trend that suppresses its chronic nonspecific inflammation under this dosage.
(3) function of promoting blood circulation to disperse blood clots of the present invention---Mice Auricle microcirculation test
Summary: be coated with the present invention outward for Mice Auricle, can increase local microvascular open number, the expansion blood capillary is outstanding with venule, increases red cell velocity in the venule, points out this medicine that certain function of promoting blood circulation to disperse blood clots is arranged.
1, purpose: examine under a microscope the intravital mouse Auricle Microcirculation and change, be subjected to the function of promoting blood circulation to disperse blood clots of reagent in order to reflection.
2, medicine and instrument:
(1) the present invention and excipient (forming) by glycerol, white vaseline, octadecanol, glyceryl monostearate.
(2) barium sulfide, pentobarbital sodium.
(3) microscope, micrometer, cold light source.
3, animal: Kunming mouse, male and female are regardless of, and female for not producing and not having pregnantly, body weight 24-27g is provided by Experimental Animal Center.Conventional feed is fed, and drinking-water is not limit, 22-25 ℃ of experiment room temperature, relative humidity 50-60%.
4, grouping and method:
Grouping: 20 animals are divided into 2 groups at random, 10 every group.
(1) excipient matched group: 0.1g/ ear * 2 such as glycerol innings are coated with.
(2) of the present invention group: 0.1g/ ear * 2 innings are coated with.
Method:
1) experiment is preceding 2 days, will be tried right side of mice auricle dorsal part hair with 8% barium sulfide solution and slough.
2) experiment was smeared and was subjected to the reagent secondary by drafting dosage the morning on the same day, midfeather 4 hours, and carry out microcirculation detect half an hour behind the last coating.
3) give mice through intraperitoneal anesthesia with 0.3% pentobarbital sodium solution 0.15ml/10g (45mg/kg) immediately before the detection.
4) animal is lain on the back be fixed on the Mus plate, placement coverslip under the auricle of right side, and, auricle is easily pasted mutually with slide at its periphery dropstone wax oil, be horizontal level.
5) under cold light source, observe with microscope.
6) selecting mouse ear profile lateral border blood capillary, is the object of observation with arteriole and the vein of caliber 6-8um, observes the variation of erythrocyte fluidised form and flow velocity in the vary in diameter of the open number of blood capillary, arteriole, venule and the blood capillary respectively.
5, result or conclusion:
(1) to the influence of the open number of auricle blood capillary: the present invention can increase microvascular open number.
(2) to the influence of auricle microvascular diameter: the present invention has the microvascular effect of expansion, especially with the work that act as to venule.
(3) to the influence of auricle blood capillary fluidised form and flow velocity: with the excipient matched group mutually specific energy accelerate red cell velocity.
(4) the present invention can promote the microcirculation of Mice Auricle, points out this medicine that significant function of promoting blood circulation to disperse blood clots is arranged.
(4) antipruritic test of the present invention
Summary: the present invention can obviously resist the effect of itching of causing of phosphoric acid tissue.
1, purpose: understand the histamine phosphate of Cavia porcellus local skin contact variable concentrations by this experiment after, this medicine is to the influence of its itch-threshold.
2, medicine:
(1) the present invention and excipient (forming) by glycerol, white vaseline, octadecanol, glyceryl monostearate.
(2) histamine phosphate: white powder, the solution that is mixed with variable concentrations with normal saline is used for experiment.
3, animal: Cavia porcellus, male and female are regardless of, and female for not producing and not having pregnantly, body weight 300-330g is provided by Experimental Animal Center.Conventional feed is fed, and drinking-water is not limit, 22-25 ℃ of experiment room temperature, relative humidity 50-60%.
4, grouping and method:
Grouping: 16 Cavia porcelluss are divided into 2 groups at random, 8 every group.
(1) excipient matched group: 0.1g pawl * 2 externals.
(2) of the present invention group: 0.1g/ pawl * 2 externals.
Method: in the experiment proxima luce (prox. luc), give the cropping of the right back instep of each Cavia porcellus portion, smear by group in the cropping position and correspondingly tried thing once next day, after half an hour, rub the part to minority oozing of blood point is arranged with Coarse Mesh Gauze, repaste is smeared relative medicine once, and beginning in 10 minutes after administration, drip 0.01% the 50ul/ of histamine phosphate pawl respectively with microsyringe at each agents area, later on every three minutes, dripping successively with the position that concentration increases progressively is 0.02%, 0.03%, 0.04% again ... the histamine phosphate of equivalent is till Cavia porcellus occurring and later licking metapedes.
Giving the total amount of the histamine phosphate that each animal dripped respectively in period with this section is itch-threshold.And the itch-threshold of each animal in every group carried out statistical procedures, between organizing relatively.
5, result or conclusion: smear the present invention to Cavia porcellus, the itch-threshold of its animal is apparently higher than the excipient matched group.Illustrate that this medicine has certain itching-relieving action.
Three, sanitary index testing result of the present invention:
| Test item | Unit | Testing result (average) | Limit value |
| Plumbous (Pb) | mg/kg | ＜0.08 | ≤40 |
| Hydrargyrum (Hg) | mg/kg | 0.004 | ≤1 |
| Arsenic (As) | mg/kg | ＜0.01 | ≤10 |
| Bacterial population | CFU/mL | ＜10 | ≤1000 |
| Fungi count | CFU/mL | ＜10 | ≤100 |
| Staphylococcus aureus | Do not detect | Must not detect | |
| Bacillus pyocyaneus | Do not detect | Must not detect | |
| Demodicid mite lives | Do not detect | Must not detect |
Four, Semen Persicae in the present invention's prescription is the mature seed kernel of peach, and its property hardship, sweet, flat has blood circulation promoting and blood stasis dispelling, and the moistening for dryness and softening hard mass effect can be impelled carbuncle, the softening dissipation of cicatrix; Fructus Bruceae, property hardship, cold, but external softening the hard mass removing food stagnancy, removing blood stasis with potent drugs is capable to loose the wart of dispelling, cicatrix tuberosity; Borneolum Syntheticum, the hot perfume (or spice) of property is walked string, and external has reducing swelling and alleviating pain, except that rotten antipruritic, the swollen merit of kind dissipating blood stasis; Fructus Bruceae and Borneolum Syntheticum play blood circulation promoting and blood stasis dispelling with Semen Persicae, and the softening the hard mass removing food stagnancy is anticorrosion antipruritic, disappear to control the nodular effect of cicatrix; Camphora, property is hot loose ward off turbid, the external parasite killing that can dehumidify, eliminating stasis to stop pain is changed the detumescence that stagnates, and uses alkalium in addition, property is salty, bitter, warm, but external softening the hard mass removing food stagnancy piece, blood stasis dispelling blood, killing parasites for relieving itching, each medicine is played promoting blood circulation and breaking stagnation altogether, and the softening the hard mass removing food stagnancy is eliminated pruritus, make softening, the detumescence of cicatrix and hypertrophic cicatrix, the effect of putrefaction removing itching relieving.Use glycerol, vaseline, octadecanol and glyceryl monostearate to be substrate, suitable viscosity and stretchability are arranged, also unlikely its character of change of its stable in properties, dry sterilization can not become sour, nonirritant, on skin, can form occlusive and cover, impel the hydration of keratodermatitis, make cicatrix softening, in the hope of playing the crust softening and shedding, reach the rehabilitation effect.Take a broad view of prescription, all medicines cooperatively interact, and play promoting blood circulation and breaking stagnation altogether, and the softening the hard mass removing food stagnancy is changed the scar itching-relieving action, can be used for cicatrix and keloidal rehabilitation that a variety of causes causes.
The specific embodiment
Embodiment 1: the present invention restrains numeral system by weight by following raw materials and forms fully: Semen Persicae 100g, Fructus Bruceae 50g, Borneolum Syntheticum 5g, Camphora 5g, alkalium 30g, glycerol 200g, vaseline 100g, octadecanol 5g, glyceryl monostearate 5g.
Its preparation method is as follows:
1, squeezing Semen Persicae and Fructus Bruceae are got oil, add Borneolum Syntheticum, Camphora grinding, get mixed liquor;
2, take by weighing vaseline, glyceryl monostearate, octadecanol, the mixed liquor that adds step 1 carries out heating and melting in pot;
3, take by weighing glycerol and alkalium mixing mixing batter;
4, with the gains of step 3 to the emulsifying pot, again with the gains of step 2 to the emulsifying pot, emulsifying;
5, cooling, check, canned.
In step 5, with the mastic embedding in sebific duct or other satisfactory packaging materials.
Embodiment 2: the present invention restrains numeral system by weight by following raw materials and forms fully: Semen Persicae 500g, Fructus Bruceae 300g, Borneolum Syntheticum 50g, Camphora 50g, alkalium 300g, glycerol 600g, vaseline 500g, octadecanol 50g, glyceryl monostearate 50g.
Its preparation method is as follows:
1, squeezing Semen Persicae and Fructus Bruceae are got oil, add Borneolum Syntheticum, Camphora grinding, get mixed liquor;
2, take by weighing vaseline, glyceryl monostearate, octadecanol, the mixed liquor that adds step 1 carries out heating and melting in pot;
3, take by weighing glycerol and alkalium mixing mixing batter;
4, with the gains of step 3 to the emulsifying pot, again with the gains of step 2 to the emulsifying pot, emulsifying;
5, cooling, check, canned.
In step 5, with the mastic embedding in sebific duct or other satisfactory packaging materials.
Claims (3)
1. the medicine of a dispeling scar is characterized in that: be prepared from by weight by following raw materials:
Semen Persicae 100-500 part Fructus Bruceae 50-300 part Borneolum Syntheticum 5-50 part
Camphora 5-50 part alkalium 30-300 part glycerol 200-600 part
Vaseline 100-500 part octadecanol 5-50 part glyceryl monostearate 5-50 part.
2. the preparation method of the medicine of a dispeling scar as claimed in claim 1, it is characterized in that: its preparation method is as follows:
Its preparation method is as follows:
1) squeezing Semen Persicae and Fructus Bruceae are got oil, add Borneolum Syntheticum, Camphora grinding, get mixed liquor;
2) take by weighing vaseline, glyceryl monostearate, octadecanol, the mixed liquor that adds step 1 carries out heating and melting in pot;
3) take by weighing glycerol and alkalium mixing mixing batter;
4) with the gains of step 3 to the emulsifying pot, again with the gains of step 2 to the emulsifying pot, emulsifying;
5) cooling, check, canned.
3. the preparation method of the medicine of dispeling scar according to claim 2 is characterized in that: in step 5, with the mastic embedding in sebific duct or other satisfactory packaging material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101930440A CN101181385B (en) | 2007-11-28 | 2007-11-28 | Medicament for dispelling scar and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101930440A CN101181385B (en) | 2007-11-28 | 2007-11-28 | Medicament for dispelling scar and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101181385A true CN101181385A (en) | 2008-05-21 |
| CN101181385B CN101181385B (en) | 2010-09-29 |
Family
ID=39446896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101930440A Active CN101181385B (en) | 2007-11-28 | 2007-11-28 | Medicament for dispelling scar and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101181385B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579920A (en) * | 2012-03-27 | 2012-07-18 | 郑州密丽药业有限公司 | Chinese medicine ointment for curing human-body scars and preparation method thereof |
| CN105748801A (en) * | 2016-04-01 | 2016-07-13 | 郑州密丽药业有限公司 | Medicine for removing scars and preparing method thereof |
| CN105943691A (en) * | 2016-06-21 | 2016-09-21 | 赵锋 | Traditional Chinese medicine preparation for treating keloid and preparation method thereof |
| CN110946908A (en) * | 2018-09-21 | 2020-04-03 | 湖北疤梅纳生物科技有限公司 | Formula for treating hyperplastic scars and preparation process |
-
2007
- 2007-11-28 CN CN2007101930440A patent/CN101181385B/en active Active
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579920A (en) * | 2012-03-27 | 2012-07-18 | 郑州密丽药业有限公司 | Chinese medicine ointment for curing human-body scars and preparation method thereof |
| CN102579920B (en) * | 2012-03-27 | 2013-10-02 | 郑州密丽药业有限公司 | Chinese medicine ointment for curing human-body scars and preparation method thereof |
| CN105748801A (en) * | 2016-04-01 | 2016-07-13 | 郑州密丽药业有限公司 | Medicine for removing scars and preparing method thereof |
| CN105943691A (en) * | 2016-06-21 | 2016-09-21 | 赵锋 | Traditional Chinese medicine preparation for treating keloid and preparation method thereof |
| CN110946908A (en) * | 2018-09-21 | 2020-04-03 | 湖北疤梅纳生物科技有限公司 | Formula for treating hyperplastic scars and preparation process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101181385B (en) | 2010-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6681482B2 (en) | Topical pharmaceutical composition for the treatment of various wound wounds on the skin and method for preparing the same | |
| CN103721131B (en) | A kind of Chinese medicine suppository and its preparation method treating women's chronic pelvic inflammatory disease | |
| CN101979041B (en) | Chinese medicinal preparation for treating various dermatoses | |
| CN100404054C (en) | Decoction Chinese medicine sterilizing antiphlogistic, preparation and use thereof | |
| CN105106655B (en) | A kind of prosthetic burn and scald ointment and preparation method thereof | |
| CN103041184B (en) | Traditional Chinese medicine composition for external use for curing chronic eczema of children and preparation method thereof | |
| CN103751663A (en) | Traditional Chinese medicine externally applied preparation for treating perianal eczema and preparation method thereof | |
| CN101744976B (en) | Sterilizing and antipruritic lotion and preparation method thereof | |
| CN101181385B (en) | Medicament for dispelling scar and preparation method thereof | |
| CN104306841B (en) | A kind of Chinese medicinal lotion for treating gynaecological imflammation, scytitis, pruritus | |
| CN102240260B (en) | Medicament for treating colpoxerosis and preparation method thereof | |
| CN101214341A (en) | Medicine preparation for curing psoriasis and preparation thereof | |
| CN103721138B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating rosacea | |
| CN101317873B (en) | Hyperosteogeny ache-reliving plaster and preparation method thereof | |
| CN101053612B (en) | External applied traditional Chinese medicine vagina cleaning agent for curing gynecopathy and vagina cleaning ointment thereof | |
| CN103007034B (en) | Traditional Chinese medicine composition used for treatment of residual second-degree burn wound, and preparation method thereof | |
| CN109453314A (en) | A kind of Chinese medicine composition fumigated for gynaecology's postoperative rehabilitation | |
| CN101991520A (en) | Washing-free bath cream with sleeping function and preparation method thereof | |
| CN101332286B (en) | Traditional Chinese medicine composition for treating skin disease and preparation method thereof | |
| CN102697835A (en) | External medicament for treating skin diseases | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN103028060A (en) | Traditional Chinese medicine composition for treating infant acute eczema and preparation method of traditional Chinese medicine composition | |
| CN102697855B (en) | Medicinal composition for treating skin diseases | |
| CN107582633B (en) | External traditional Chinese medicine preparation for treating urticaria and preparation method thereof | |
| CN101940652B (en) | Chinese medicinal liniment for treating psoriasis, multiple kinds of stubborn dermatitis and pruritus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Zhengzhou Mili Pharmaceutical Co., Ltd. Assignor: Su Yikang Contract fulfillment period: 2008.6.30 to 2018.6.29 contract change Contract record no.: 2008410000009 Denomination of invention: Medicament for dispelling scar and preparation method thereof License type: Exclusive license, exclusive permission Record date: 2008.9.12 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.6.30 TO 2018.6.29 Name of requester: ZHENGZHOU MI LI PHARMACEUTICAL CO., LTD. Effective date: 20080912 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Zhengzhou Mili Pharmaceutical Co., Ltd. Assignor: Su Yikang Contract fulfillment period: 2008.6.30 to 2018.6.29 contract change Contract record no.: 2008410000009 Denomination of invention: Medicament for dispelling scar and preparation method thereof License type: Exclusive license Record date: 2008.9.12 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Zhengzhou Mili Pharmaceutical Co., Ltd. Assignor: Su Yikang Contract fulfillment period: 2008.6.30 to 2018.6.29 contract change Contract record no.: 2008410000009 Denomination of invention: Medicament for dispelling scar and preparation method thereof License type: Exclusive license Record date: 2008.9.12 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.6.30 TO 2018.6.29; CHANGE OF CONTRACT Name of requester: ZHENGZHOU MI LI PHARMACEUTICAL CO., LTD. Effective date: 20080912 |
|
| ASS | Succession or assignment of patent right |
Owner name: ZHENZHOU MILI CHEMICAL CO., LTD Free format text: FORMER OWNER: SU YIKANG Effective date: 20100709 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20100709 Address after: 450001 Cedar Road, Zhengzhou hi tech Industrial Development Zone, Henan, Zhengzhou 6, China Applicant after: Zhengzhou Mili Pharmaceutical Co., Ltd. Address before: 450001 Cedar Road, Zhengzhou hi tech Industrial Development Zone, Henan, Zhengzhou 6, China Applicant before: Su Yikang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |